LL-37 (Cathelicidin): The Antimicrobial & Immune Peptide Evidence Reviewed (2026)

LL-37 is the only cathelicidin peptide the human body makes, and it sits at a strange crossroads in the research world. Scientists have studied it for decades as a natural antibiotic and immune signal, yet the same molecule that helps fight infection can also drive painful skin disease when it runs out of control. This review walks through what the evidence actually shows, separates the proven biology from the marketing, and points you to the primary literature so you can check the claims yourself.

What Is LL-37?

LL-37 is a small protein fragment your immune system produces. The name describes it literally: the chain starts with two leucine amino acids ("LL") and is 37 amino acids long. It is the only member of the cathelicidin family that humans make, which is why it gets so much attention.

It does not float around the body in its final form. Instead, your cells make a larger precursor protein called hCAP18. When the body needs LL-37, enzymes cut the active 37-amino-acid piece off the end of that precursor. That cutting step matters more than it sounds, and we will come back to it, because when the cutting goes wrong, the peptide can cause harm instead of help.

A wide range of cells make it. Neutrophils (a type of white blood cell) store it in granules and release it at sites of infection. Skin cells, gut lining cells, lung cells, and other surfaces produce it too. That spread tells you something: LL-37 is part of the body's first line of defense, stationed at the borders where the outside world meets the inside.

Its shape is the key to how it works. In the right environment, LL-37 folds into a helix that is "amphipathic," meaning one side is water-loving and the other is fat-loving. It also carries a positive electrical charge. Bacterial membranes carry a negative charge. Opposites attract, the peptide latches onto the microbe, and its fat-loving face buries into the membrane and tears it open (Antimicrobial Peptides of the Cathelicidin Family, Int J Mol Sci 2025, PMID 40869425).

You will also see LL-37 sold in the gray-market "research peptide" world as an injectable or oral product. That is a very different thing from the molecule your body makes on demand, and we cover the safety gap below.

How LL-37 Works

LL-37 is not a one-trick molecule. The research describes at least three overlapping jobs, and that breadth is part of why it is so heavily studied and so hard to turn into a drug.

Direct microbe killing. This is the classic role. The positively charged peptide is drawn to the negatively charged surface of bacteria, then punches holes in the membrane until the cell leaks and dies. The same general approach works against some fungi and enveloped viruses. Reviews credit LL-37 with activity against a broad list of bacteria, fungi, and viruses in the lab (Antimicrobial Peptides of the Cathelicidin Family, Int J Mol Sci 2025, PMID 40869425).

Endotoxin neutralizing. When gram-negative bacteria break apart, they release a fragment called LPS that can trigger a dangerous, runaway immune reaction (a big driver of sepsis). LL-37 binds LPS and blunts that signal. So the peptide does not just kill the bug; it also helps clean up the inflammatory debris the dying bug leaves behind (Human antimicrobial peptide LL-37 prevents spread of local infection, Inflamm Res 2025, PMID 40063262).

Immune signaling. LL-37 acts as a chemical flare. It recruits immune cells to the scene, nudges wound-healing processes like new blood vessel growth and skin-cell migration, and tunes inflammation up or down depending on context. This is where the molecule gets complicated, because the same signaling that helps a wound heal can, in the wrong setting, light a fire that will not go out (Human antimicrobial peptide LL-37 prevents spread of local infection, Inflamm Res 2025, PMID 40063262).

The Vitamin D Connection

Here is a link most people miss. The gene that codes for LL-37 (called CAMP) has a switch in its control region that responds to vitamin D. When active vitamin D binds that switch, the cell makes more LL-37.

This is not a fringe idea. In the classic experiments, immune cells detect a microbe through a sensor called TLR2, ramp up the machinery that turns vitamin D into its active form, and that active vitamin D then drives production of LL-37 to fight the invader. Researchers showed that blood from people with low vitamin D was worse at supporting this antimicrobial response, which helped explain the long-noticed link between vitamin D deficiency and tuberculosis risk (Vitamin D-Cathelicidin Axis, Immune Netw 2020, PMID 32395364).

The honest takeaway: maintaining healthy vitamin D levels supports your body's own LL-37 production through a well-mapped pathway. That is a much better-supported approach than injecting a gray-market peptide. If your interest in LL-37 is immune health, the vitamin D angle is the part with real human grounding.

When LL-37 Turns Against You

The most important thing to understand about LL-37 is that more is not always better. The same peptide that defends you can drive disease when it is overproduced or cut into the wrong fragments. The skin section below covers the specifics, but the headline is this: LL-37 is a double-edged sword, and the research community treats it that way (Cathelicidin LL-37 in inflammatory skin disease, Ann Dermatol 2012, PMID 22577261).

The Evidence By Use

LL-37 gets discussed for several uses. The strength of the evidence varies a lot, and most of the human data sits at the topical or local level, not whole-body injection. Here is a side-by-side look.

Use	What's claimed	Strength of evidence	Notes
Antimicrobial defense (innate immunity)	Natural antibiotic against bacteria, fungi, viruses	Strong in lab; mechanistic in humans	Core, well-established biology; vitamin D pathway is human-grounded
Topical wound healing	Speeds healing of chronic ulcers	Mixed (early positive, later negative)	Small trial positive at low dose; larger phase IIb failed overall
Diabetic foot ulcers (topical cream)	Faster ulcer closure	Early/limited (one small RCT)	Single positive trial; needs replication
Rosacea / psoriasis	Targeting LL-37 may help	Strong as a disease driver, not a treatment	LL-37 here is the problem, not the cure
Anti-cancer (intratumoral)	Shrinks tumors	Early/experimental	Lab and early-phase work only; not a treatment
Injectable/oral "research peptide" for general health	Boosts immunity, fights infection	Weak to none	No solid human safety or benefit data for this route

Antimicrobial Defense

This is LL-37's best-established role, and it is genuinely impressive biology. In the lab, the peptide kills a long list of microbes by wrecking their membranes, neutralizes bacterial toxins, and interferes with the slimy biofilms that make infections hard to treat (Antimicrobial Peptides of the Cathelicidin Family, Int J Mol Sci 2025, PMID 40869425).

In living humans, the strongest evidence is indirect but solid: your own LL-37, produced through the vitamin D pathway, is part of why you fight off infections like tuberculosis (Vitamin D-Cathelicidin Axis, Immune Netw 2020, PMID 32395364).

The catch is the leap from "natural antibiotic in the body" to "antibiotic you can take." Turning LL-37 into an actual drug runs into hard problems. It gets chewed up quickly by enzymes in the body, it can be toxic to human cells at the doses needed to kill stubborn microbes, and it is expensive to make. These are not minor footnotes. They are the reason LL-37 has been studied for decades without becoming a pill you can buy at the pharmacy (Antimicrobial Peptides of the Cathelicidin Family, Int J Mol Sci 2025, PMID 40869425).

Wound Healing

Wound healing is where LL-37 has been tested most directly in humans, and the story is a useful lesson in not getting ahead of the data.

An early first-in-human trial in hard-to-heal venous leg ulcers looked encouraging. Patients got LL-37 at different concentrations or a placebo. The two lower doses healed faster than placebo, with the lowest dose showing the clearest benefit. Oddly, the highest dose worked no better than placebo, hinting that there is a sweet spot and that piling on more peptide backfires (Treatment with LL-37 in venous leg ulcers, Wound Repair Regen 2014, PMID 25041740).

Then came the bigger, more rigorous test. A multicenter phase IIb trial enrolled 148 patients with hard-to-heal venous leg ulcers and ran two LL-37 doses against placebo, all with compression therapy. The result was honest and sobering: across the full study population, LL-37 did not heal ulcers significantly better than placebo. A subgroup of very large ulcers showed a signal, but subgroup findings are exactly the kind of result that needs confirmation before anyone leans on it (Evaluation of LL-37 in venous leg ulcers, Wound Repair Regen 2021, PMID 34687253).

That arc, promising small trial then disappointing larger trial, is common in medicine and is the reason single positive studies should be read with caution. The peptide was safe in these trials. It just did not deliver the clear benefit the early work suggested.

There is one more topical wound study worth noting. A smaller randomized, double-blind trial tested an LL-37 cream on diabetic foot ulcers and reported faster healing than the control. That is a real, positive result, but it is one modest study and has not been confirmed in larger trials yet (Efficacy of LL-37 cream in diabetic foot ulcers, Arch Dermatol Res 2023, PMID 37480520).

The fair summary for wound healing: plausible biology, one solid negative phase IIb trial, and a couple of small positive ones. Not proven. For other peptides studied in tissue repair with their own evidence gaps, see our BPC-157 research studies overview and the comparison of oral versus injectable BPC-157 evidence.

Rosacea And Psoriasis

This is the most counterintuitive part of the LL-37 story, and it is the best reason to be skeptical of "more LL-37 is good" marketing. In two common skin diseases, LL-37 is not a helper. It is a key part of what makes the disease happen.

In rosacea, the problem is not just how much LL-37 there is, but how it gets cut. Rosacea skin has too much protease activity, so the cathelicidin precursor gets chopped into abnormal fragments. Those fragments trigger inflammation, redness, and the visible blood vessels (telangiectasias) that define the condition. Research has shown that LL-37 sets off the NLRP3 inflammasome, an inflammation alarm, and that blocking that alarm in mice reduces the rosacea-like skin reaction (LL-37 Ignites NLRP3 Inflammasomes in Rosacea, J Invest Dermatol 2021, PMID 34565561).

In psoriasis, LL-37 is overproduced in the inflamed plaques. It binds to the patient's own DNA released from dying cells and turns that self-DNA into a danger signal that immune cells (plasmacytoid dendritic cells) read as an alarm, kicking off a self-feeding inflammatory loop. So the body's own defense peptide ends up driving an attack on the skin (Cathelicidin LL-37 in inflammatory skin disease, Ann Dermatol 2012, PMID 22577261).

The practical message is blunt: in these conditions, scientists are looking for ways to block or calm LL-37, not boost it. Anyone selling LL-37 as a do-no-harm immune booster is ignoring a large body of evidence that, in the wrong setting, it does real harm.

Cancer

You will see claims that LL-37 fights cancer. The honest version is "it is being studied, and the picture is mixed." In some lab and animal models, LL-37 or related peptides appear to slow or kill tumor cells, and direct injection into tumors has been explored in early-phase work. But LL-37 has also been linked to the growth of certain cancers in other studies, which is a serious red flag against treating it as a clean anti-cancer agent.

This is experimental territory, not a treatment. There is no approved LL-37 cancer therapy, and the dual-edged behavior, helpful in some contexts and harmful in others, is exactly why (LL-37 tumor and cancer research on PubMed).

LL-37 As A Supplement Or Research Peptide

Here is the gap between the science and what is sold online. Most of the credible LL-37 research is either basic biology (how the molecule works), local/topical (creams on ulcers), or about your body's own production via vitamin D. Almost none of it supports buying injectable or oral LL-37 to boost immunity or fight infection.

A few things to keep straight:

• It is not an FDA-approved treatment. LL-37 is not approved as a drug for any condition. The clinical trials that exist were topical wound studies, and the biggest one failed its main goal.
• "Research use only" means nobody is standing behind it. Injectable LL-37 sold for "research" routes around the rules that govern real drugs and supplements. You take on all the quality and safety risk.
• Dosing is not standardized. There is no established human dose for systemic LL-37, because no regulator has approved one.
• Quality varies wildly. Peptides from gray-market vendors can be impure, mislabeled, or contaminated. For what real quality control looks like, see our peptide vendor quality standards guide.

If your goal is supporting the LL-37 your body already makes, the vitamin D pathway is the evidence-backed lever, and it is something you can discuss with a doctor using a simple blood test.

Safety

LL-37's safety story has two very different chapters depending on the dose and the route.

At the low, local doses used in the human wound trials, LL-37 was generally well tolerated. The phase IIb venous ulcer trial reported a reassuring safety profile even though the peptide did not beat placebo (Evaluation of LL-37 in venous leg ulcers, Wound Repair Regen 2021, PMID 34687253).

At higher concentrations, the picture changes. LL-37 is cationic and amphipathic, the very features that let it tear apart bacterial membranes, and at high enough doses it can also damage human cells. The literature describes toxicity to several human cell types and the ability to rupture red blood cells (hemolysis) at elevated concentrations. This is the central problem in turning it into a systemic drug: the dose that kills tough microbes can also hurt you (Antimicrobial Peptides of the Cathelicidin Family, Int J Mol Sci 2025, PMID 40869425).

A few more cautions worth knowing:

• Inflammatory skin conditions. If you have rosacea or psoriasis, the evidence suggests LL-37 can worsen, not help, the underlying inflammation. Adding more is the wrong direction.
• Injectable gray-market products. These lack the safety track record of the topical trial material, dosing is guesswork, and sterility depends entirely on the seller.
• Drug interactions and conditions are unknown for systemic use. Because there is no approved systemic product, there is no reliable map of who should avoid it.

The short version: topical, low-dose LL-37 looked safe in trials; high-dose and systemic use is a real toxicity concern, and the gray-market route adds quality risk on top.

How LL-37 Compares To Alternatives

LL-37 does not exist in isolation. Here is how it lines up against the things people weigh it against.

Versus other immune-support peptides. Peptides like thymosin alpha-1 have been studied for immune modulation with their own (still limited) evidence base, and they work by different mechanisms. None of these is a proven over-the-counter immune cure. For a different research peptide in the immune-modulation lane, see our thymosin alpha-1 research review.

Versus boosting your own LL-37 with vitamin D. This is the comparison that matters most and gets ignored most. The vitamin D to cathelicidin pathway is well mapped in humans, and correcting a vitamin D deficiency is cheap, safe, and doctor-guided. If the appeal of LL-37 is "natural immune support," addressing vitamin D status is the better-evidenced move (Vitamin D-Cathelicidin Axis, Immune Netw 2020, PMID 32395364).

Versus conventional antibiotics. Standard antibiotics are proven, regulated, and dosed precisely. LL-37 is not an antibiotic you can prescribe, despite its antibiotic-like biology, because the stability, toxicity, and cost problems have never been solved well enough to make a usable drug (Antimicrobial Peptides of the Cathelicidin Family, Int J Mol Sci 2025, PMID 40869425).

Versus topical wound-care peptides like BPC-157. Different research lane, different evidence. Both are studied for tissue repair; neither is an approved wound drug. Our BPC-157 research studies overview covers that body of work.

The short version: LL-37 is mechanistically fascinating and central to your natural defenses, but as a product to buy, it is outrun by its own marketing. The proven lever is supporting your body's own production through vitamin D, not injecting the peptide.

Who LL-37 Research Is Relevant For

To be clear about the practical reality:

• Researchers and clinicians studying innate immunity, skin disease, and wound healing have good reason to care about LL-37. It is a real and important molecule.
• People with rosacea or psoriasis should know LL-37 is part of what drives their condition, which is why dermatology research is trying to dial it down, not up.
• People interested in immune health are better served by the vitamin D pathway and a conversation with a doctor than by gray-market peptides.
• Anyone considering injectable or oral LL-37 should know there is no approved product, no standard dose, a failed lead clinical trial, and real toxicity at high concentrations.

This is a molecule worth understanding, not a supplement worth buying.

Frequently Asked Questions

Is LL-37 FDA-approved for any use?

No. LL-37 is not approved as a drug for any condition. The main human trials tested it as a topical cream on chronic leg ulcers, and the largest, most rigorous trial (148 patients) found no significant benefit over placebo. Any injectable or oral LL-37 sold online is an unapproved "research" product, not an approved medicine.

Does LL-37 actually fight infections in the body?

Your own LL-37 is a real part of your innate immune defense, and the lab evidence that it kills bacteria, fungi, and some viruses is strong. The well-supported way to support it is through vitamin D, which directly drives LL-37 production. There is no good human evidence that taking LL-37 as a supplement boosts immunity.

Why is LL-37 linked to skin diseases like rosacea?

In rosacea, the cathelicidin precursor gets cut into abnormal fragments that trigger inflammation, redness, and visible blood vessels. LL-37 also activates an inflammation alarm called the NLRP3 inflammasome. In psoriasis, overproduced LL-37 helps set off a self-attacking immune loop. So in these conditions, LL-37 is a driver of the disease, not a treatment.

Is injectable LL-37 safe to use?

There is no approved injectable LL-37 and no standard human dose, so there is no reliable safety map for systemic use. At high concentrations, LL-37 can damage human cells and rupture red blood cells. Gray-market products also carry quality, purity, and sterility risks. Talk to a licensed clinician before considering any injectable peptide.

What is the connection between vitamin D and LL-37?

The gene that makes LL-37 has a vitamin D-responsive switch, so active vitamin D directly increases LL-37 production. Low vitamin D is linked to weaker antimicrobial defense, which helped explain the long-known tie between vitamin D deficiency and tuberculosis risk. Keeping vitamin D in a healthy range is the evidence-backed way to support your own LL-37.

This article is for educational purposes only and is not medical advice. Talk to a licensed healthcare provider before starting any new treatment.